The global race to develop a COVID-19 vaccine is far from conventional. An effective vaccine would offer one of the few credible exit paths from the world’s worst public health and economic crisis in recent history. Is a pull for R&D essential or optional?
CGD Policy Blogs
The Race for a COVID-19 Vaccine: An Overview of Current Proposals and Our Contribution in Bringing in the Missing Middle
Much rests with the successful development and introduction of an effective COVID-19 vaccine. It may be our only path towards fully reopening our economies without fear of future outbreaks and associated health and economic impacts. See here for an overview of recent vaccine initiatives.
Every country faces the same fundamental challenge in the face of the COVID-19 pandemic. Their economies and societies cannot fully return to “normal” until we have a safe and effective vaccine. And achieving that goal quickly is not easy. We see four big problems.
DFIs are well positioned to address five pressure points in the COVID-19 response that need financing. Let’s unpack these one by one.
On what basis have some European policymakers decided that it’s wise to reopen schools? And how will those calculations differ in low- and middle-income countries?
If we want to make sure everyone can get quality products without financial burden, here’s why we think value-based pricing and competitive markets beat the “fair pricing” approach.
Despite decades of investment, TB remains a global crisis. Each year, TB kills 1.6 million people—making it the world’s deadliest infectious diseases. We have set out to develop a solution: what we ultimately called the Market-Driven, Value-Based Advance Commitment (MVAC), a mechanism to create and guarantee a market for better TB treatment, if and when such a treatment becomes available.
From Vision to Architecture: Three Questions to Guide the Global Family Planning Movement Towards 2030
The start of 2020 marks a critical juncture for Family Planning 2020. Authors explore the Beyond 2020 Vision and pose three central questions for the Core Partners and family planning community to consider.
With a new government in majority and Brexit certainty greater, there is an opportunity for the UK to make a global mark in four areas of global health and development.
Over the past two decades, several global health institutions have attempted to improve public health by influencing the characteristics of health product markets, including pricing, quality, overall production, and the supplier and product landscapes. We examine the role of Gavi, the Vaccine Alliance in market shaping.